SYGNIS reports results for the first quarter of 2013 - Seite 2

Outlook
SYGNIS confirmed the outlook stated in the Annual Report 2012, published on 30 April 2013. According to this guidance, the company expects further commercial agreements and first revenues from product sales in 2013. The company plans to reach break-even in 2014 fiscal year.

Figures for the first quarter of fiscal year 2013 and comparative figures in accordance with IFRS and pro forma figures (Q1 2012 pro forma information includes SYGNIS old and X-Pol)
[Numbers in €million]	Q1 2013	Q1 2012 pro forma	Q1 2012
Revenues	0.1	0.1	0.0
Total Expenses	1.3	2.7	0.3
EBIT	-1.2	-4.0	-0.3
Net results for the period	-1.2	4.0	-0.3
Operating Cash Flow	-0.9	-1.7	-0.1
Liquidity at year-end	0.2	1.5	0.1

The interim report for the first quarter, ended 31 March 2013, is available at www.sygnis.de.

For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: [phone]
Email: [e-mail]

About SYGNIS Pharma AG: www.sygnis.de  
After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi^® and is currently developing other products in the field of Next Generation Sequencing.

### Disclaimer
Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Press release (PDF)

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: SYGNIS Pharma via Thomson Reuters ONE

HUG#1701774

--- End of Message ---

SYGNIS Pharma
Im Neuenheimer Feld 515 Heidelberg Germany